547,599 Shares in ADMA Biologics Inc $ADMA Acquired by Legal & General Group Plc

Key Points

• Legal & General Group Plc acquired 547,599 shares of ADMA Biologics during the second quarter, worth approximately $4.58 million and representing about 0.24% of the company.
• Institutional ownership remains significant at 75.68%, with BlackRock, State Street, Sachem Head, Westfield Capital and Capital Research among the company’s largest holders.
• ADMA reported quarterly EPS of $0.16, in line with estimates, while revenue reached $124.39 million, up 2% year over year but slightly below forecasts. Analysts’ consensus rating is Hold, with an average price target of $18.67.

Legal & General Group Plc acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 547,599 shares of the biotechnology company's stock, valued at approximately $4,583,000. Legal & General Group Plc owned approximately 0.24% of ADMA Biologics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of ADMA. BlackRock Inc. bought a new stake in shares of ADMA Biologics during the second quarter worth $321,037,000. State Street Corp lifted its stake in shares of ADMA Biologics by 0.3% during the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company's stock valued at $248,014,000 after acquiring an additional 35,614 shares during the period. Sachem Head Capital Management LP boosted its holdings in ADMA Biologics by 27.0% in the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company's stock valued at $207,480,000 after acquiring an additional 2,415,000 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in ADMA Biologics by 36.9% in the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company's stock valued at $127,551,000 after acquiring an additional 1,886,105 shares during the last quarter. Finally, Capital Research Global Investors increased its position in ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company's stock worth $121,067,000 after purchasing an additional 3,383,559 shares during the period. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Trading Up 0.7%

NASDAQ ADMA opened at $9.58 on Friday. The stock has a 50-day simple moving average of $9.13 and a 200 day simple moving average of $10.31. The company has a market capitalization of $2.15 billion, a PE ratio of 13.69 and a beta of 0.78. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $20.46.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The company had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The company's revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.14 EPS. Research analysts forecast that ADMA Biologics Inc will post 0.78 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Raymond James Financial started coverage on ADMA Biologics in a report on Wednesday, June 10th. They set an "outperform" rating and a $21.00 price objective for the company. Zacks Research lowered shares of ADMA Biologics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, August 4th. Weiss Ratings reiterated a "hold (c)" rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Mizuho dropped their price target on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating for the company in a research note on Wednesday, July 15th. Finally, Canaccord Genuity Group cut their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $18.67.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source